Continuing Education Online Courses


Browse online courses available for Continuing Education Credit.

Click here to view more online courses and resources for clinicians.

2021 CE Courses
Collapse Practical Barriers in Cancer Immunotherapy Treatment

Published February 23, 2021

 

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

 

This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
 

At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


Faculty
Sigrun Hallmeyer, MD

Medical Director, Cancer Service Line

Medical Director, Cancer Survivorship Center

Advocate Lutheran General Hospital

Chair, Executive Committee

Association of Community Cancer Centers, Immuno-Oncology Institute


 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
  • Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

 


Continuing Education Information

 

Credit Available: February 23, 2021 - February 23, 2022

 

Estimated time to complete activity: 1.25 hours

 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

  PIM_logo.pngsitc_log_color.png

 

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2606-H01-P)

Type of Activity: Application


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 23, 2021 through February 23, 2022 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for "Practical Barriers in Cancer Immunotherapy Treatment." 
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: February 23, 2021

Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.25 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Practical Barriers in Cancer Immunotherapy Treatment
    Collapse Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer

    The goal of this activity is to improve clinicians' ability to manage patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The two cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

     

    This activity is intended for oncologists, pathologists, and surgeons.

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Clinical trial design and data from recent trials for recurrent or metastatic HNSCC
    • Have greater competence related to
      • Identifying patient and tumor characteristics that can help guide treatment selection in patients with recurrent or metastatic HNSCC across the disease spectrum
      • Developing an evidence-based treatment plan for a patient with recurrent or metastatic HNSCC across the disease spectrum
      • Recognizing and mitigating treatment- and immune-related adverse events (irAEs)

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: January 25, 2021 - January 25, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

    Original Course Date: February 08, 2021

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer
    Collapse Updates on Immune Modulators in Lung Cancer: Have We Met the Need?

    https://img.medscapestatic.com/thumbnail_library/943953.jpg?interpolation=lanczos-none&resize=300:*

     

    This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to increase clinicians' understanding of timmune modulators used in the management of patients with metastatic non-small cell lung cancer (NSCLC)

     

     

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the mmune modulators being studied to treat patients with metastatic NSCLC (mNSCLC), including how they may manipulate the immune system to improve recognition of cancer cells, tumors, and metastases

    • Have increased knowledge regarding the ongoing immunotherapy clinical trials in the management of patients with mNSCLC

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: January 13, 2021 - January 13, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

    Certificate in Cancer Immunotherapy

     

     

    Original Course Date: January 13, 2021

    Approved Credit:
  • : 0.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Updates on Immune Modulators in Lung Cancer: Have We Met the Need?
    Collapse  Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis

    Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis

     

    This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to increase clinicians' understanding of the immune system and avenues of immune modulation beyond the currently available checkpoint inhibitors.

     

     

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the unmet medical need in patients with cancer whose disease does not respond to or becomes resistant to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and/or cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition

    • Have increased knowledge regarding the avenues of immune modulation beyond PD-1/PD-L1 and CTLA-4 inhibition to improve immune recognition of cancer cells and tumors

    • Have increased knowledge regarding the mid-to-late stage clinical trial data on the use of novel strategies to modulate the immune system to treat patients with cancer

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: December 23rd, 2020 - December 23rd, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

    Certificate in Cancer Immunotherapy

     

     

    Original Course Date: December 23, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO  Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis
    2020 CE Courses
    Collapse Mechanisms of Immune-Related Adverse Events

    Published December 24, 2020

     

    Course Description

    This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Pradnya Patil, MD, FACP

    Hematology/Oncology Fellow

    Taussig Cancer Institute, Cleveland Clinic


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the mechanisms of peripheral and central immune tolerance.
    • Describe the biological pathways involved in mediating autoimmune reactions.
    • Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: December 24, 2020 - December 24, 2021

     

    Estimated time to complete activity: 0.5 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2520-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Pradnya Patil, MD, FACP: Nothing to disclose

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period December 24, 2020 through December 24, 2021 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for "Mechanisms of Immune-Related Adverse Events." 
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: December 24, 2020

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Mechanisms of Immune-Related Adverse Events
    Collapse Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade

    Published December 1, 2020

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.


    Click on image for FREE PREVIEW


     

     

     

     

     

     

     

     

     

     

    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Robert L. Ferris, MD, PhD
    Hillman Professor of Oncology
    Director, UPMC Hillman Cancer Center
    Associate Vice Chancellor for Cancer Research
    University of Pittsburgh Medical Center, Pittsburgh, PA

     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Mechanisms of Checkpoint
    Blockade in Immunotherapy

    • Describe the basis for co-stimulation in T cell activation and priming.
    • Explain the mechanisms and consequences of co-inhibitory immune checkpoint receptors (ICR).
    • Identify negative downstream regulatory motifs and pathways associated with ICR signaling.
    • Distinguish the distinct activities of antibodies that target PD-1 compared to those that target PD-L1

    Biomarkers of Response to ICB and General Clinical Utility

    • Describe major biomarkers for patient eligibility for the use of immune checkpoint blockade across cancers (PD-L1 expression and extent, IFN signature, CD8 infiltration, Tumor Mutational Burden) and their relative value for prediction of clinical benefit.
    • Distinguish between validated and investigational biomarkers.
    • Describe the use of biomarkers to predict ORR, PFS and OS.
    • Identify patient-specific factors that may predict response (tumor burden, prior chemotherapy exposure, age, gender, site of disease, prior radiotherapy, etc.).
    Immune Checkpoint Inhibitors and Combination Approaches
    • Describe general clinical benefits of ICB with PD-1 or CTLA-4 monotherapy, or ICB combinations (including IO+IO and IO+other cancer therapy combinations).
    • Distinguish the benefits, dose and schedules of combination ICB versus the benefits, dose and schedule of conventional therapies (chemotherapy, radiation therapy and targeted therapies).
    • Identify validated vs investigational ICB combinations, and relevant cancer types.
    Monitoring Response to Checkpoint Blockade
    • Distinguish response criteria in ICB vs standard cancer treatment.
    • Describe kinetics and patterns of response to ICB.
    • Distinguish pseudoprogression from true disease progression.
    • Identify when to suspend or discontinue ICB treatment.


     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  December 1, 2020
    Date of CE Expiration: December 1, 2022
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Physicians / Nurses / Pharmacist

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Robert

    Ferris

    Aduro Biotech, Inc; Amgen; Astra-Zeneca/MedImmune; Bain Capital Life Sciences; BMS; EMD Serono; GSK; Iovance Biotherapeutics, Inc; Lilly; MacroGenics, Inc; Merck; Nanobiotix; Numab Therapeutics AG; Oncorus, Inc; Ono Pharmaceutical Co. Ltd; Pfizer; PPD (Benitec, Immunicum); Regeneron Pharmaceuticals, Inc; Tesaro; Torque Therapeutics; TTMS; VentiRx Pharmaceuticals:Consulting Fees

    Astra-Zeneca/MedImmune; BMS; Merck; Tesaro; TTMS:Contracted Research

     

    Janssen, Eli Lilly, Scibase, DermTech, BMS, Pfizer:Partner Consulting Fees

     

    Regeneron, Janssen, BMS, Abbvie, Novartis, BI, Castle Biosciences, Eli Lilly: Partner Contracted Research

     

    Jose

    Lutzky

    Castle, Kimera Labs, Array, Iovance: Consulting Fees
     

    BMS, Novartis, Iovance, Replimune, Regeneron: Contracted Research


    Method of Participation and Request for Credit
    During the approved time period (12/1/20 - 12/1/22) participants must read the learning objectives and faculty disclosures and study the educational activity.

    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: December 01, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade
    Collapse Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts

    Published October 26, 2020

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.


    Click on image for FREE PREVIEW


     

     

     

     

     

     

     




    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Hussein Tawbi, MD, PhD
    Deputy Chair and Professor, Department of Melanoma Medical Oncology
    Director of Melanoma Clinical Research & Early Drug Development
    Co-Director, MD Anderson Brain Metastasis Clinic
    University of Texas MD Anderson Cancer Center, Houston, TX
     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basis of Tumor Immunosurveillance and Immunotherapy

    • Describe how the immune system recognizes and eliminates cancer cells, including the concept of immunologic memory.
    • Characterize the function of specific immune cell populations in mediating tumor immunotherapy and/or immune suppression.
    • Distinguish between immunosurveillance, immunoediting and immunotherapy of cancer.
    • Identify the implications of immune depleted, excluded and infiltrated tumor microenvironments.
    • Identify how both central and peripheral tolerance can impact immunosurveillance and immunotherapy.
    • Describe the difference between primary and acquired resistance to immunotherapy.
    • Apply concepts of the cancer-immunity cycle to identify how biomarkers inform and influence tumor immunotherapy.

    Immunologic effects of other therapies

    • Describe the immunologic effects of standard cancer therapeutics on the tumor microenvironment and immune system.
    • Describe the potential impact of other, non-cancer agents, on tumor immunotherapy responses and toxicities.
    • Characterize the impact of standard cancer treatments on the efficacy of cancer immunotherapy.
    • Characterize the impact of standard cancer treatments on the toxicity of cancer immunotherapy.
    • Distinguish total body versus focal radiotherapy effects.
    • Recognize the impact of intratumoral injection and other local therapies on the tumor microenvironment and anti-tumor immune response.


     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  10/26/20
    Date of CE Expiration: 10/26/22
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Physicians / Nurses / Pharmacist

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Hussein

    Tawbi

    Genentech, BMS, Novartis, Merck, Array: Consulting Fees

    Genentech, BMS, Novartis, Merck, GSK: Contracted Research
     

    Silvia

    Formenti

    Grant/Research support from: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron,Eisai, Merck: Contracted Research

    Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Accuray: Honoria


    Method of Participation and Request for Credit
    During the approved time period, 10/26/20 - 10/26/22, participants must read the learning objectives and faculty disclosures and study the educational activity.

    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: October 26, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts
    Collapse Immunotherapy for the Treatment of Breast & Gynecologic Cancers

    Published August 11, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the still emerging applications of Breast and Gynecologic Cancer Immunotherapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for Breast and Gynecologic Cancer.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Evanthia Roussos Torres, MD, PhD
    Assistant Professor of Medicine, Oncology
    University of Southern California
    Norris Comprehensive Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
    • Implement cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 8/11/20 - 8/11/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2249-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Evanthia Roussos Torres, MD, PhD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 8/11/20 through 8/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Breast & Gynecologic Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

    Original Course Date: August 11, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Breast & Gynecologic Cancers
    Collapse Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts

    Published August 3, 2020

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 1: Basic Immunology Concepts, will cover some of the key immunology needed to understand the rest of the certificate program.

    Click on image for FREE PREVIEW



    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Robert L. Ferris, MD, PhD
    Hillman Professor of Oncology
    Director, UPMC Hillman Cancer Center
    Associate Vice Chancellor for Cancer Research
    University of Pittsburgh Medical Center, Pittsburgh, PA

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Properties of the Immune System

    • Describe the differences between innate immunity and adaptive immunity.
    • Describe the differences between humoral immunity and cellular immunity.
    • Describe the concept of self/non-self discrimination and immunologic memory.

    Cells and Tissues of the Immune System

    • Distinguish between the basic cell types involved in the immune response and their function, including B cells, T cells, natural killer (NK) cells, monocytes/macrophages and dendritic cells (DC).
    • Describe the architecture and functions of various immunologic tissues including the thymus, spleen, lymph nodes and bone marrow.

    Innate Immunity

    • Describe the key components of innate immunity including pattern recognition receptors and cells of the innate immune system.
    • Describe the function and regulation of innate immunity.
    • Describe how activation of innate immunity influences adaptive immune response.
    • Recognize how host cell death influences innate immunity. 

    Adaptive Immunity

    • Describe the components of the adaptive immune system including both humoral and cellular immunity.
    • Describe the function and regulation of adaptive immunity.
    • Define immune tolerance.
    • Describe how immune tolerance impacts adaptive immunity.

    Antigen Presentation

    • Distinguish class I and class II MHC antigen presentation.
    • Describe antigen uptake, processing and presentation.
    • Describe the concept of cross-presentation.

    Effector Immune Responses

    • Identify the cell populations involved in effector immune responses.
    • Describe the different mechanisms of effector functions.
    • Describe how effector functions are regulated.

    Inhibitory and Activating Immune Regulation

    • Describe the functions of major suppressive cell populations (regulatory T cells [Treg], and myeloid derived suppressor cells [MDSC])
    • Describe immunological synapses.
    • Describe the molecular mechanisms of immune cell activation.
    • Describe the molecular mechanisms of immune cell inhibition.
    • Distinguish between immune cell activation and inhibition of suppression as a pharmacological strategy.

    Integration of the Immune Response

    • Describe how the arms of the immune system interact.
    • List the host factors that influence the immune response.
    • List the environmental factors that influence the immune response.


     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  August 3, 2020
    Date of CE Expiration: August 3, 2022
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts to correctly answer 24 out of 30 questions) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Physicians / Nurses / Pharmacist

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Robert

    Ferris

    Aduro Biotech, Inc; Amgen; Astra-Zeneca/MedImmune; Bain Capital Life Sciences; BMS; EMD Serono; GSK; Iovance Biotherapeutics, Inc; Lilly; MacroGenics, Inc; Merck; Nanobiotix; Numab Therapeutics AG; Oncorus, Inc; Ono Pharmaceutical Co. Ltd; Pfizer; PPD (Benitec, Immunicum); Regeneron Pharmaceuticals, Inc; Tesaro; Torque Therapeutics; TTMS; VentiRx Pharmaceuticals:Consulting Fees

    Astra-Zeneca/MedImmune; BMS; Merck; Tesaro; TTMS:Contracted Research

     

    Janssen, Eli Lilly, Scibase, DermTech, BMS, Pfizer:Partner Consulting Fees

     

    Regeneron, Janssen, BMS, Abbvie, Novartis, BI, Castle Biosciences, Eli Lilly: Partner Contracted Research


    Method of Participation and Request for Credit
    During the period 8/3/20 through 8/3/22 participants must read the learning objectives and faculty disclosures and study the educational activity.

    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better (unlimited attempts to correctly answer 24 out of 30 questions) and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: August 03, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts
    Collapse Immunotherapy for the Treatment of Microsatellite Instability-High Cancers

    Published July 29,2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers, provides background on MSI and an overview of immunotherapy treatment for MSI-high populations. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for MSI-high cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    John C. Leighton, Jr., MD
    Division Chair, Hematology and Medical Oncology
    Einstein Healthcare Network

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe microsatellite instability and the implications for immunotherapy treatment
    • Provide cancer immunotherapy treatment for microsatellite instability – high cancers
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 7/29/20 - 7/29/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2214-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    John C. Leighton, Jr., MD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/29/20 through 7/29/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: July 29, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Microsatellite Instability-High Cancers
    Collapse Optimizing Management of Adverse Events Associated with Immunotherapy

    While it is well established that immunotherapies have unique toxicity profiles, effective management is not clearly defined and a challenge for many cancer teams. As evidence emerges on severity and onset of immune-related adverse events (irAEs), it is imperative that clinicians stay abreast of strategies to improve awareness, risk-assessment, monitoring, and management of irAEs including dosing modifications for immunotherapies. Experts will discuss these critical issues as well as the importance of a coordinated approach with multiple specialists for effective irAE management.

     

    This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

     

     

    Learning Objectives:

    • Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
    • Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Optimizing Management of Adverse Events Associated with Immunotherapy
    Collapse Life After Immunotherapy: Coordinating Care and Survivorship Plans

    Effective survivorship care requires coordination among a team of specialists, as well as counseling and education that enables patients to effectively manage their post-treatment health and well-being. As the long-term effects of checkpoint inhibitors are incorporated into survivorship planning, a multidisciplinary panel will discuss evidence-based strategies to provide a framework to address the unique needs of patients treated with immunotherapy.

     

    This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

     

     

    Learning Objectives:

    • Apply recent guidelines and expert recommendations for the creation of comprehensive survivorship plans for patients who have received immune checkpoint inhibitors
    • Plan strategies on developing survivorship plans within your multidisciplinary cancer care team

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Life After Immunotherapy: Coordinating Care and Survivorship Plans
    Collapse Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

    Image previewImmunotherapy has permeated the cancer treatment landscape among several tumor types and treatment settings. With key late-stage clinical trials underway, immunotherapy experts provide critical updates on emerging data, recent approvals, and promising immunotherapy combinations with other classes of agents. Updates will be provided across solid tumors with opportunities to ask critical clinical questions and receive expert answers.

     

    This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

     

     

    Learning Objectives:

    • Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
    • Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
    • Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
    • Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: July 24, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations
    Collapse Immunotherapy for the Treatment of Lung Cancer

    Published July 15, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through an in-depth case study. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Deepa Rangachari, M.D.
    Assistant Professor of Medicine, Harvard Medical School
    Thoracic Oncology Program, Beth Israel Deaconess Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 7/15/20 - 7/15/21

    Approximate Time to Complete:  60 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2190-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Deepa Rangachari, MD: Contracted research support from Bristol Myers Squibb, Novocure, and Abbvie/Stemcentrx; consulting fees from Astra Zeneca, DynaMed, and Advance Medical/Teladoc Health


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/15/20 through 7/15/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Lung Cancer.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

    Original Course Date: July 15, 2020

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Lung Cancer
    Collapse Refining Patient Selection for Biomarker-Directed Immunotherapy

    Access Course

     

    As diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.

     

    This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

     

    Learning Objectives:

    • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
    • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: June 10, 2020 - February 28, 2021

     

    Developed through a collaboration between SITC and PlatformQ.

    sitc_log_color.png     

    logo

     

    Original Course Date: June 10, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Refining Patient Selection for Biomarker-Directed Immunotherapy
    Collapse Immunotherapy for the Treatment of Skin Cancers

    Published May 26, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Ryan J. Sullivan, MD
    Assistant Professor of Medicine
    Harvard Medical School, Boston, MA
    Division of Hematology/Oncology, Department of Medicine
    Massachusetts General Hospital, Boston MA

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for skin cancers. 
    • Identify common side effects of immunotherapy agents.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  75 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2143-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.30 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Immunotherapy for the Treatment of Hepatocellular Carcinoma

    Originally published May 26, 2020 (Updated June 9. 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Anuradha Krishnamurthy, MD
    Assistant Professor of Medicine
    University of Pittsburgh School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the characteristics of liver immunobiology
    • Implement cancer immunotherapy treatment for HCC and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2142-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Anuradha Krishnamurthy, MD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Collapse Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy?

    Access Course

     

    Case Studies in Head and Neck Cancer: What Is the Best Sequence of TherapyThe role of immunotherapy in the treatment of patients with advanced squamous cell carcinoma of the head and neck (SCCHN) is explored through two cases.

     

    The cases presented are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice.

     

    This activity is intended for hematologist/oncologists, surgeons, and other healthcare professionals who treat patients with SCCHN.

     

    The goal of this activity is to increase understanding of current approaches to treating advanced SCCHN with immunotherapy.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical study designs, as well as efficacy and safety findings, from trials that have evaluated immune checkpoint inhibitor regimens in patients with recurrent or metastatic SCCHN.
    • Have greater competence related to identifying tumor characteristics and other clinical features that guide treatment selection in patients with recurrent or metastatic SCCHN.
    • Have greater competence related to strategies for monitoring and managing treatment-related adverse events.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: May 15, 2020 - May 15, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

     

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

     

    Original Course Date: May 15, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy?
    Collapse Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?

    Access Course

     

    Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? Experts discuss the current role of checkpoint inhibition in hepatocellular cancer (HCC) as well as the emergence of combination therapies.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of HCC.

     

    This activity is intended for hematologists/oncologists, gastroenterologists, nurses/nurse practitioners, pharmacists, and other healthcare professionals who treat patients with advanced hepatocellular cancer.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) in managing unresectable HCC.
    • Have greater competence related to identifying when an ICI should be considered for a patient with unresectable/advanced HCC.
    • Have greater competence related to managing immune-related adverse events (irAEs) in patients with unresectable HCC.

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: May 8, 2020 - May 8, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

     

    View Guidelines Here.

     

    Original Course Date: May 08, 2020

    Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ANCC: 0.75 hours Contact Hour
  • ACPE: 0.75 hours CEU

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?
    Collapse Immunotherapy for the Treatment of Head and Neck Cancer

    Originally published April 30, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Michael Gibson, MD, PhD FACP
    Associate Professor of Medicine
    Director of Translational Research for Head and Neck Oncology
    Director of Translational Therapeutics for Esophago-Gastric Oncology
    Vanderbilt-Ingram Cancer Center
    Vanderbilt University Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for head and neck cancers. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 4/30/20 - 4/30/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2066-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: April 30, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Head and Neck Cancer
    Collapse Test Your Skills: Treating Bladder Cancer

    Access Course

     

     Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface.

     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    This activity is intended for Hem/Onc specialists, urologists, and emergency medicine specialists.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, evidence-based treatment, counseling, and follow-up related to patients with advanced urothelial cancer.

     

    Learning Objectives:

    • Have greater competence related to ordering appropriate testing to determine patient eligibility for therapy in advanced urothelial carcinoma (UC).
    • Have greater competence related to prescribing appropriate therapy in a patient with advanced UC based on patient and disease-specific factors.
    • Have greater competence related to providing appropriate conseling and follow-up for a patient receiving treatment for advanced UC.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 28, 2020 - April 28, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

     

     

     

    View Guidelines Here.

     

    Original Course Date: April 28, 2020

    Approved Credit:
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Test Your Skills: Treating Bladder Cancer
    Collapse The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers

    Access Course

     

    The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial CancersRead about the latest advances in immuno-and targeted therapies for treating patients with advanced cervical and endometrial cancers.

     

    This activity is intended for hematologist/oncologists, obstetrics/gynecologists, and other healthcare professionals who treat patients with cervical and endometrial cancers.

     

    The goal of this activity is to increase understanding of current standards and new strategies for the treatment of advanced cervical and endometrial cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the current standard of care for patients with advanced cervical and endometrial cancers.
    • Have increased knowledge regarding the clinical trial safety and efficacy data for novel therapies, both alone and in combination with other novel agents, in advanced cervical and endometrial cancers.
    • Demonstrate greater confidence in their ability to interpret clinical trial data of novel agents in order to understand the impact on the treatment paradigm in advanced cervical and endometrial cancers.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 10, 2020 - April 10, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: April 10, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers
    Collapse Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer

    Access Course

     

    Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer Experts discuss the use of checkpoint inhibitors in the first and second line for advanced urothelial carcinoma as well as future directions.

     

    This activity is intended for oncologists, urologists, emergency department physicians, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to increase understanding in the latest advances in immunotherapy for the treatment of patients with advanced bladder cancer.

     

    Learning Objectives:

    • Have increased knowledge regarding the current role for immune checkpoint inhibitors (ICIs) in the treatment of advanced urothelial carcinoma (UC).
    • Have increased knowledge regarding novel ICIs and novel combination trials in advanced UC.
    • Have greater competence related to incorporating emerging data into clinical practice when managing patients with advanced UC.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 8, 2020 - April 8, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

     

     

     

    View Guidelines Here.

     

    Original Course Date: April 08, 2020

    Approved Credit:
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    Originally published March 31, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Pedro Barata, MD, MSc
    Assistant Professor of Medicine
    Deming Department of Medicine
    Section of Hematology/Oncology
    Tulane University School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for genitourinary malignancies. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 3/31/20 - 3/31/21

    Approximate Time to Complete:  1 hour
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     


    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2051-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: March 31, 2020

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse Immunotherapeutic Approaches in TNBC: The Latest Data

    Access Course

     

    Immunotherapeutic Approaches in TNBC: The Latest DataDrs Emens and Adams discuss the emerging data for checkpoint inhibition in both the metastatic and neoadjuvant disease settings for TNBC.

     

    This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of TNBC.

     

    Learning Objectives:

    • Have increased knowledge regarding the biologic rationale for using immune checkpoint inhibitors (ICIs) to manage patients with TNBC.
    • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs in the management of TNBC
    • Have increased knowledge regarding the ongoing clinical trials that may affect standards of care across the treatment continuum for TNBC

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 22, 2020 - Mar. 22, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: March 22, 2020

    Approved Credit:
  • : 0.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immunotherapeutic Approaches in TNBC: The Latest Data
    Collapse Case Studies in Lung Cancer: Test Your Skills

    Access Course

     

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    This activity is intended for hematologist/oncologist specialists.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, biomarker testing, evidence-based frontline treatment, and potential treatment-related adverse events of patients with advanced lung cancer.

     

    Learning Objectives:

    • Select appropriate diagnostic and biomarker tests to guide treatment selection for a patient with advanced lung cancer.
    • Order an appropriate, evidence-based frontline treatment regimen for a patient with advanced lung cancer.
    • Provide patient education for potential treatment-related adverse events.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 18, 2020 - Mar. 18, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Lung Cancer Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: March 19, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Lung Cancer: Test Your Skills
    Collapse Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?

    Access Course

     

    Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.

     

    This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
    • Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 4, 2020 - Mar. 4, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Melanoma Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: March 04, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?